Year-over-year earnings per share growth for the last twelve months: verrica.com (VRCA)

verrica.com - graphic logo of issuer VRCA

Verrica Pharmaceuticals (VRCA) is implementing eco-packaging to reduce its plastic footprint. The quarterly EPS trend captures current dynamics, where -1920.90 represents the latest level. Revenues are based on the sale of the drug YCANTH. Business resilience is supported by an autonomous demand cycle for biotechnology, rendering the asset defensive during recessionary periods.

VRCA: verrica.com Year-over-year earnings per share growth for the last twelve months 07/04/2022 - 11/18/2026

Verrica Pharmaceuticals Inc. (VRCA) - metric breakdowns and financial figures

- company stock exchange capitalization indicators:
Summary company analytics:Verrica Pharmaceuticals Inc. - VRCA
Manufactured product of verrica.com

The use of robotic production lines in the manufacturing of Verrica Pharmaceuticals (VRCA) drugs minimizes costs, directly impacting earnings per share. This metric measures the rate of change in the final quarterly financial result, reflecting capital management efficiency and the operational resilience of the business. Analyzing the trend of quarterly earnings per share allows for the identification of hidden margin risks before they are reflected in market prices.

Competitors of Verrica Pharmaceuticals (VRCA)

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth